Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Are outcomes for childhood leukaemia in Australia influenced by geographical remoteness and Indigenous race?

Presenting features, biology and outcome for childhood leukaemia are known to vary by ethnic origin, geographic location and socioeconomic group. This study aimed to compare presentation patterns, follow-up and clinical outcomes in Indigenous and non-Indigenous children with acute leukaemia in Australia, and to assess the impact of remoteness and area-based socioeconomic disadvantage on outcome.

Research

Exposure to diagnostic radiological procedures and the risk of childhood acute lymphoblastic leukemia

Diagnostic irradiation of the mother during pregnancy increases the risk of childhood acute lymphoblastic leukemia

News & Events

World-first clinical trial in ‘man’s best friend’ could unlock treatment breakthrough for kids with cancer

The Kids Research Institute Australia is leading a unique clinical trial in pet dogs that could pave the way for a new immunotherapy treatment for one of the most common childhood cancers, Sarcoma.

News & Events

Trial of new antibody gives hope to children suffering from brain cancer

Children with aggressive brain cancers could soon have access to a significant new treatment option, using a unique antibody that stops cancer cells from repairing themselves.

News & Events

The Kids Research Institute Australia Cancer Centre Researcher wins Cancer Council WA Fellowship

Cancer Council WA has awarded a Post-Doctoral Fellowship to Dr Ben Wylie, for his project to help kids with sarcoma.

Research

Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease

Invasive fungal disease (IFD) remains a challenging complication of treatment for paediatric acute leukaemia. Consensus fungal treatment guidelines recommend withholding chemotherapy to facilitate immune recovery in this setting, yet prolonged delays in leukaemia therapy increase risk of relapse.

Perth dogs helping to fight cancer

Associate Professor Lesterhuis said the gel, developed with the help of chemists at The University of Western Australia, could revolutionise the way solid tumours were treated.

News & Events

Researchers unlock key to slowing leukaemia progression in kids

When three-year-old Flo Parker injured her hip on a camping trip five years ago, her parents thought it would be nothing more than a common childhood injury.

News & Events

Ependymoma Awareness Day

Ethan was not even two when he was diagnosed with a rare type of brain tumour known as an ependymoma.

Research

DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3

DYRK1A is a serine/threonine kinase encoded on human chromosome 21 (HSA21) that has been implicated in several pathologies of Down syndrome (DS), including cognitive deficits and Alzheimer's disease. Although children with DS are predisposed to developing leukemia, especially B cell acute lymphoblastic leukemia (B-ALL), the HSA21 genes that contribute to malignancies remain largely undefined. Here, we report that DYRK1A is overexpressed and required for B-ALL. Genetic and pharmacologic inhibition of DYRK1A decreased leukemic cell expansion and suppressed B-ALL development in vitro and in vivo.